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The research on protein aggregation and amyloid formation is motivated by the fact that 
amyloid formation in tissue is harmful and associated with several debilitating diseases 
including Alzheimer’s disease (AD) and systemic amyloidosis such as transthyretin 
(ATTR) amyloidosis. Nevertheless, their beneficial roles in Nature have recently been 
identified, and artificial self-assembling of amyloid structure for various applications are 
emerging. In this thesis, disease-related amyloid aggregates were studied with a focus on 
their detection and interactions with other proteins in biofluid. Also, the usefulness of 
functionalized self-assembled amyloid structure as a detection system for pathological 
amyloid is investigated. 
New affinity proteins based on Affibody molecules were developed targeting stable 
protofibrils formed by an engineered version of amyloid-b (Ab) peptide, called Ab42CC. 
The developed affinity proteins also recognize protofibrils of wild-type Ab42, and showed 
selective binding to protofibrils over other aggregated forms of Ab. Binding kinetics of 
these new binders to Ab42CC protofibrils were determined. These proteins have potential 
to be used in diagnostic or even therapeutic applications. 
An enhanced method was developed for the detection of small ATTR aggregates. A 
nanofibril, which was functionalized with the antibody-binding Z domain was the new 
molecule in the improved method. The efficiency of the new method for sensitive 
detection of ATTR aggregates was studied. The result of this study was very encouraging 
and could potentially be used in the future for high sensitivity detection of ATTR 
aggregates. 
The potential interactions of Ab42CC protofibrils and Ab42wt fibrils with other proteins 
in serum and cerebrospinal fluid from patients with AD and non-AD were studied. More 
than hundred proteins with diverse functionality were identified to bind to Ab42CC 
protofibrils and Ab42wt fibrils. It was shown that different Ab conformations have a 
distinct set of binding partners, and the binding is enhanced upon aggregation of Aβ. 
Many of the identified proteins may have potential as AD biomarkers. 
In conclusion, this thesis has developed new research tools and a methodology to 
detect amyloid aggregates as well as studied potential interactions of these aggregates 
with other proteins, which could advance our understanding about protein aggregation 
and disease. 
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Life is a fine-tuned complex biological system and more than 200 different cell 
types interact and make up the human body. A cell comprises several different 
biomolecules, and nucleic acids and proteins are two of the four major 
macromolecules. The nucleic acids, deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) store and transfer all information required for the 
synthesis of a protein. Proteins are the most versatile biomolecules in living 
organisms and they perform a large variety of functions including metabolism, 
processing, storage and transport of other molecules as well as providing 
structure and mechanical support (Lehninger et al., 1992, Berg et al., 2002). A 
protein consists of amino acids linked together via peptide bonds into a 
polypeptide chain, and the unique order of the amino acids defines the primary 
structure of the molecules. The polypeptide chain folds upon itself and forms 
secondary structural elements, a-helix and b-sheet. These elements are further 
organized to produce the three-dimensional (3D) protein structure, the tertiary 
and quaternary structure. 
Proteins are synthesized on ribosomes using information encoded by mRNA, 
and these proteins must subsequently fold into their unique 3D structure in order 
to function (Fig. 1.1, top panel) (Tyedmers et al., 2010). It is generally accepted 
that the necessary information needed for the proper folding of a protein lies in 
its primary structure. This is known as the thermodynamic hypothesis of protein 
folding, and was established through a series of experiments performed by 
Anfinsen and colleagues in the 1950s (Anfinsen et al., 1954, Anfinsen et al., 
1955). As tribute to his work Anfinsen was awarded the 1972 Nobel Prize in 
Chemistry (Anfinsen, 1973). However, in the crowded cellular environment, a 
newly synthesized polypeptide faces several challenges including environmental 
stress, mutation or translational errors that increase the risk of misfolding and 
aggregation. To avoid this situation, the cell has evolved an advanced protein 
quality control machinery, which is comprised of a specialized group of proteins 
referred to as molecular chaperones. Chaperones, also known as heat shock 
1 Introduction 
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proteins (HSPs), have the capacity to assist folding of the newly synthesized 
protein as well as enable partially misfolded protein to refold into its correct 3D 
conformation and thereby gain functional activity (Fig. 1.1). About 20-30% of 
proteins synthesized in a mammalian cell need chaperone assistance to adopt the 
correct conformation (Hartl et al., 2011). 
 
Figure 1.1 Upon release from the translation machinery, the nascent polypeptide folds into native 
conformation, when necessary with the assistance from chaperones, and subsequently form the 
higher order structures (top panel). However, due to environmental stress or other reasons, the 
newly synthesized protein can be misfolded. The misfolded protein can either be degraded by the 
cellular degradation system or refold into its native conformation through chaperone machinery. If 
the cellular quality control is insufficient and refolding or degradation fails, the partially misfolded 
and misfolded proteins can form either amorphous aggregates or a highly ordered structural 
conformation called amyloid. The amorphous aggregates and pre-amyloid aggregates may be 
disaggregated or degraded. Figure modified from refs. Tyedmers et al., 2010, Hartl et al., 2011. 
In addition, the cell uses an extensive proteostasis network, composed of several 
hundred proteins that are responsible for trafficking, disaggregation, and 
proteolytic cleavage. Prior to clearance, misfolded proteins undergo 
ubiquitination that directs them to the proteasome and subsequent degradation 
(Ciechanover and Schwartz, 2002, Glickman and Ciechanover, 2002), while 
aggregated proteins are ubiquitinated and degraded through aggrephagy, a 
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selective form of macroautophagy (Yamamoto and Simonsen, 2011). However, 
in certain scenario the proteostasis network may be insufficient or 
malfunctioning, and misfolded proteins deposit in the intracellular or 
extracellular compartment. Misfolded proteins that escape degradation can adopt 
a highly ordered fibrillar conformation rich in b-sheet known as amyloid (Fig. 
1.1, bottom panel). 
The deposition of amyloid in tissue have severe consequences and is involved 
in several debilitating diseases including Alzheimer’s disease and Parkinson’s 
disease. However, not all amyloid structures are harmful, some have a useful 
biological function and are termed functional amyloid. Also, amyloid structures 
can be functionalized with desired function. 
Detection of disease-related amyloid aggregates and examination of the 
interaction of such aggregates with other proteins is the focus of this thesis. The 
usefulness of functionalized amyloid in the pathological amyloid detection 
systems is also investigated. 
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The term amyloid was first introduced in 1854 by the German physician Rudolf 
Virchow, and is derived from the Latin amylum and the Greek amylon that means 
cellulose or starch-like. Nevertheless, in 1859 Friedreich and Kekule 
demonstrated that the composition of amyloid was not carbohydrate, but 
proteinaceous (reviewed in ref. Sipe and Cohen, 2000). In the following sections, 
the general characteristics of amyloid, the beneficial and the harmful roles of 
amyloid, how amyloid is formed, and polymorphisms of amyloid will be 
discussed. 
2.1 Characteristics of amyloid 
Amyloid is characterized by a fibrillar morphology, typical structural cross-β 
sheet conformation, and affinity for specific dyes (Divry and Florkin, 1927, 
Cohen and Calkins, 1959, Eanes and Glenner, 1968). Amyloid fibrils found in 
tissue deposits (Fig. 2.1a) appear as unbranched twisted fibers of ca. 7–10 nm in 
diameter and up to several microns long when analyzed by transmission electron 
microscopy (TEM) (Fig. 2.1b) (Cohen and Calkins, 1964) or atomic force 
microscopy (AFM) (Chamberlain et al., 2000). All amyloid, regardless of which 
peptide or protein that builds the fibril, share a structural conformation known 
as cross-β sheet structure, which was first analyzed by X-ray fiber diffraction in 
1968 (Eanes and Glenner, 1968). The X-ray fiber diffraction pattern of amyloid 
fibril shows two reflections, one at 4.7 Å, which corresponds to distance between 
two neighboring β stand in β-sheet packing and one at ca. 10 Å, which 
corresponds to β stands within β-sheet (Fig. 2.1c). More recent high-resolution 
structural data obtained from X-ray crystallography, solid-state NMR, and small 
angle X-ray scattering complemented well with the X-ray fiber diffraction 
pattern in which the β-sheet secondary structure is arranged perpendicular to the 
fibril axis (Fig. 2.1di) through the intramolecular hydrogen bonds between 
2 The amyloid fold of proteins 
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strands in the β-sheet (Knowles et al., 2007). Amyloid exhibit apple green 
birefringence in polarized light upon binding to Congo red (Holder Puchtler, 
1962) and an intense fluorescent signal with 440 nm excitation and 490 nm 
emission maxima upon binding to thioflavin T (ThT) (Vassar and Culling, 
1959). 
 
Figure 2.1 Structural features of amyloid. a) A micrograph showing amyloid-b deposits stained 
with Congo red in a section from the brain of an AD patient. b) TEM micrograph of an amyloid 
fibril, produced from synthetic wild-type Aβ42 peptide, showing unbranched twisted character. c) 
X-ray fiber diffraction from amyloid fibrils showing cross-b diffraction pattern. d) 3D structure 
obtained from an Aβ42 fibril using NMR (Luhrs et al., 2005), showing β-sheet packing at atomic 
level in which β-sheet running perpendicular to the fibril axis (i) and top view of a β-sheet in fibril 
arrangement (ii). Congo red stained micrograph was kindly provided by Westermark GT, 
diffraction photograph was adopted from ref. Serpell, 2014 with permission and Aβ fibril structure 
was produced using PDB accession no. 2BEG (NMR structure of Aβ42 fibril). 
2.2 Amyloid—what they do 
A broad range of fatal degenerative diseases arises from the deposition of 
amyloid in different tissues. At present, a total of 36 peptides or proteins have 
been identified to form amyloid in human, and each protein is associated with a 
specific disease (Sipe et al., 2016). A selection of amyloid-forming proteins and 
associated diseases are listed in Table 2.1. 
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Table 2.1 Examples of peptides or proteins that form extracellular amyloid or intracellular amyloid 
inclusions in human and their associated diseases. 
Peptide/proteina Target organs Associated disease 
a-Synuclein (a-Syn) CNS Parkinson’s disease, Dementia with Lewy 
bodies, and Multiple system atrophy 
Amyloid-b peptide (Ab) CNS Alzheimer’s disease, Hereditary cerebral 
hemorrhage with amyloidosis 
Apolipoprotein A-I (ApoAI) Heart, liver, 
kidney, PNS, 
testis, and skin 
ApoAI amyloidosis 
Apolipoprotein A-II (ApoAII) Kidney ApoAII amyloidosis 
Huntingtin exon 1 (HttEx1) CNS Huntington’s disease 
Immunoglobulin heavy chain 
(AH) 
All organs except 
CNS 
AH amyloidosis 
Immunoglobulin light chain 
(AL) 
All organs except 
CNS 
AL amyloidosis 
Islet amyloid polypeptide 
(IAPP) 
Islets of 
Langerhans, 
insulinomas 
Type II diabetes and insulinoma 
Lysozyme (Lys) Kidney Lysozyme amyloidosis 
Serum amyloid A (AA) All organs except 
CNS 
AA amyloidosis 
Transthyretin (TTR) Heart, PNS, eye SSA, FAP, and FAC  
Table adapted from Sipe et al., 2016. 
CNS, Central nervous system; PNS, Peripheral nervous system; SSA, Senile systemic amyloidosis; FAP, 
Familial amyloid polyneuropathy; FAC, Familial amyloid cardiomyopathy. 
 
Amyloid fibrils are mainly deposited in the extracellular space. However, 
intracellular inclusion is not rare e.g., Aa-synuclein (AaSyn) deposition in 
Parkinson’s disease (PD) and Islet amyloid polypeptide (AIAPP) deposits in 
islet of Langerhans. Amyloid deposits can occur in a single organ or in multiple 
organs. When amyloid is deposited in a single organ, it is termed localized 
amyloidosis. In localized amyloidosis, the amyloid protein is synthesized in the 
organ affected by the deposition. When amyloid is deposited in multiple organs, 
the condition is termed systemic amyloidosis (Sipe et al., 2016). In systemic 
amyloidosis, the amyloid proteins are mainly produced by the liver or by plasma 
cells. 
Besides humans, animals can also develop amyloidosis. Of the 36 proteins or 
peptides currently known to form amyloid in human diseases, nine proteins or 
peptide are also known to form amyloid in animals such as immunoglobulin light 
chain (AL) and serum amyloid A (AA), which form amyloid in cow, cats, horse 
and dog (Sipe et al., 2016). 
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The amyloid structure was first discovered in the context of disease, but not 
all amyloid structures are harmful and a group of amyloid structures have 
biological functions. Amyloid with beneficial functions in living systems is 
known as functional amyloid (Fowler et al., 2006). Many organisms ranging 
from bacteria to human use amyloid structure to gain a variety of functions 
(Fowler et al., 2007, Knowles and Mezzenga, 2016). For example, curli fibrils 
produced from the CsgA protein are used by Escherichia coli (E. coli) for 
biofilm formation (Chapman et al., 2002), and fibrils of the Pmel17 protein is 
involved in mammalian skin pigmentation (Fowler et al., 2006). Notably, in 
recent years, amyloids have become the center of interest in nanomaterial 
sciences for functionalization in various technological applications. Amyloid in 
functional aspect will be discussed in more depth in chapter 4. 
2.3 Mechanism of amyloid fibril formation 
The amyloid fibril formation process is modeled as a nucleation-dependent 
polymerization, with three phases: a lag phase, an elongation phase, and a steady 
state (Jarrett and Lansbury, 1992) (Fig. 2.2, red curve). The native folded state 
of the protein/peptide needs to be unfolded to form fibril. The fibril formation is 
initiated by the formation of a nucleus during the lag phase, a 
thermodynamically unfavored state in the aggregation process. The nucleus has 
a different conformation than the soluble protein, which is rich in b-sheet 
structure (Serio et al., 2000), and presumably composed of oligomers although 
monomer has also been implicated (Eisele et al., 2015). Once the nucleus is 
formed, monomeric species are rapidly added to the growing polymer and 
formed aggregates that are more thermodynamically stable (Jarrett and 
Lansbury, 1993). Fibril growth occurs during the elongation phase. The 
fibrillation can be catalyzed by secondary nucleation where the surface of 
preformed fibril or fibril fragmentation act as nucleation sites (Fig. 2.2) (Cohen 
et al., 2011, Cohen et al., 2013), and dominate the reaction. The lag phase can 
be shortened or abolished by addition of pre-formed fibrils, so-called seeds 
(dotted curve in Fig. 2.2) (Jarrett and Lansbury, 1992). The end reaction state is 
a steady state where the maximum fibril growth has been reached and no 
monomer species are available to be incorporated into the growing fibril. 
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Figure 2.2 Illustration of amyloid protein fibrillation pathway. A nucleus is formed during the lag 
phase, and addition of monomer results in the formation of aggregates, which subsequently grow 
into mature fibrils. Preformed fibrils or fibril fragmentation may catalyze nucleation and this is 
called secondary nucleation. 
2.4 Polymorphism of amyloid fibril 
Amyloid-forming peptides self-assemble into fibrils with multiple 
morphologies. Unlike the functional structures, the amyloid fibrils have not been 
under evolutionary pressure to maintain a single thermodynamically stable 
conformation, which is probably the cause of different fibril morphologies 
(Pedersen et al., 2006). Polymorphism may arise already during the lag phase of 
the amyloid fibrillation pathway during which metastable intermediates are 
formed, and/or within the fibrillar form (Kodali and Wetzel, 2007). In addition, 
polymorphism can occur at the atomic level, e.g, fibrils formed by the D23N-
Ab40 peptide appeared with different atomic structures. The D23N-Ab40 is 
known as the Iowa mutation, which is associated with early-onset of AD. Some 
of the fibrils formed by D23N-Ab40 exhibit the in-register parallel b-sheet 
structure, but a majority of fibrils exhibit antiparallel b-sheet packing (Tycko et 
al., 2009, Härd, 2014). Likewise, structural polymorphism may play important 
roles in clinical phenotypes and pathology. Indeed, a recent study has 
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demonstrated differences in disease progressions between two AD patients who 
displayed distinct fibril patterns in their plaques (Lu et al., 2013). 
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Deposition of amyloid in tissue can be harmful and is associated with numerous 
diseases. Two such diseases, Alzheimer’s disease (AD) and transthyretin 
(ATTR) amyloidosis will be discussed in the following sections, since they are 
central to this thesis. 
3.1 Alzheimer’s disease 
AD is the most common cause of dementia and accounts for 60–70% of all 
diagnosed cases (Alzheimer’s Association, 2018). AD was first described by the 
German psychiatrist and neuropathologist, Alois Alzheimer, in 1906 and the 
disease was named after him. During a brain autopsy of his 55-year-old patient, 
Auguste Deter, who had been suffering from progressive memory loss and 
confusions, he noted the presence of abnormal neuritic plaques around neurons 
and twisted neurofibrils inside the neuron. These two distinctive pathologies are 
today known as amyloid plaque and neurofibrillary tangles (NFTs), the two 
pathological hallmarks of AD (Alzheimer et al., 1995, O'Brien and Wong, 2011).  
The amyloid plaque consists of several proteins of which amyloid-b (Ab) is 
the major one. Ab is an enzymatic cleavage product of the amyloid-b protein 
precursor (AbPP). Ab is produced both in non-AD and AD brains. In non-AD 
brain, Ab peptides are usually degraded, whereas in AD brain, Ab accumulates 
as plaque outside of the neuron. The NFTs are found inside the cells and mainly 
composed of tau protein. Tau is a microtubule-associated protein in the neuron 
that interacts with tubulin and promotes its assembly into microtubules and 
stabilizes the microtubule network (Iqbal et al., 2010). In the AD brain, tau 
becomes hyperphosphorylated (p-tau), sequesters normal tau and disassembles 
the microtubules network, and consequently the p-tau forms tangles (Alonso et 
al., 2001). 
3 Amyloid in disease pathology 
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AD may develop because of genetic abnormalities; however, the percentage 
of genetic disorder-related AD is very low (<1%) (Bekris et al., 2010). Mutations 
in the AbPP may lead to an increased Ab production and subsequent AD 
development. The Swedish mutation, which is a double mutation 
(KM670/671NL) of AbPP that is known as APPSW, lies adjacent to the b-
secretase cleavage site and is one example of a mutation that results in an 
increased generation of Ab (Goate et al., 1991, Bekris et al., 2010). Also, 
mutations in the genes PSEN1 and PSEN2 are linked with early-onset AD. 
PSEN1 and PSEN2 encodes for presenilin 1 and presenilin 2, respectively; and 
are subunits of the enzyme g-secretase, which cleaves AbPP and releases Ab 
(see in the following section). The gene responsible for producing AbPP is 
located on chromosome 21. Individuals with Down syndrome, also known as 
trisomy 21, have an extra copy of chromosome 21, and is more susceptible to 
AD since the extra copy of chromosome 21 results in an increased production of 
Ab fragments (St George-Hyslop et al., 1987). 
Age is the main risk factor for late-onset AD (Fratiglioni et al., 1991), and 
the disease affect 3% of the people in the age group 65–74, 17% of the people 
in the age group 75–84, and nearly 50% of the people of age 85 years or older 
(Qiu et al., 2009). Nevertheless, AD is not a part of normal aging, and age is not 
itself sufficient to cause AD. A second risk factor of developing AD is epsilon 4 
allele of apolipoprotein E (apoEe4) (Saunders et al., 1993). The apoE gene exists 
in three isoforms, e2, e3, and e4. The function of apoE is to clear or degrade Ab, 
and the e4 isoform is thought to be the least efficient among the three isoforms 
of apoE. Inheriting the e4 allele confers reduced clearance of Ab and an 
increased risk of developing Ab plaque in the brain. The risk may be higher if 
two copies of e4 are inherited (Strittmatter et al., 1993). 
3.1.1  AβPP metabolism and the Aβ peptide 
AbPP is a 695–770 residue transmembrane protein with a large extracellular 
domain, a transmembrane region in which Ab is partly embedded, and a short 
cytoplasmic tail (Fig. 3.1) (Selkoe, 2001). The protein is produced in large 
amounts in the brain (Lee et al., 2008). The exact functions of AbPP remain 
unclear. However, it has been suggested that AbPP play vital roles in brain 
development, neural migration, synaptogenesis and neurogenesis (reviewed in 
ref. Coronel et al., 2018). 
AbPP is proteolytically cleaved by two distinct pathways: non-
amyloidogenic pathway which does not produce Ab, and amyloidogenic 
pathway which produces Ab. In the non-amyloidogenic pathway, AbPP is first 
cleaved by a-secretase within the Ab region between residues 16 and 17. This 
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cleavage releases a soluble extracellular fragment called sAbPPa, while the C-
terminus CFTa fragment remain anchored to the membrane. The CFTa 
fragment is then cleaved by g-secretase, which generates a non-amyloidogenic 
short peptide called p3 and an AbPP intracellular domain (AICD). Because the 
a-secretase cleaves AbPP in the middle of the Ab which precludes an intact Ab 
generation (Fig. 3.1) thus the fragment (p3) is non-amyloidogenic (O'Brien and 
Wong, 2011). a-secretase belongs to the ADAM enzyme family, which have 
been shown to take part in cell interactive events such as cell-cell fusion 
(Lammich et al., 1999). g-secretase is a multiprotein complex made of presenilin 
1 or 2, nicastrin, and Aph-1 and Pen-1 (Bergmans and De Strooper, 2010). 
 
Figure 3.1 Processing of AbPP through the non-amyloidogenic pathway involve a- and g-secretase 
cleavages with the release p3; and the amyloidogenic pathway involve b- and g-secretase cleavages, 
and the release of the Ab peptide. The bottom panel presents the Ab region in the AbPP. Possible 
cleavage into Ab sequence by different proteases are indicated. 
Production of Ab via amyloidogenic pathway is initiated by cleaving AbPP with 
b-secretase (also called BACE1; an aspartic protease) at the N-terminus of Ab 
sequence, which produces in the sAbPPb and CFTb fragments. The subsequent 
cleavage of CFTb fragments by g-secretase produces different isoforms of Ab 
peptides while leaving the AICD fragment in the cytoplasm. The most common 
isoforms of Ab are the 40-residue fragment (Ab40) and the 42-residue fragment 
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(Ab42). Ab42 is more aggregation-prone than Ab40 (Burdick et al., 1992, Jarrett 
et al., 1993). Ab is constantly produced from AbPP and immediately degraded 
by enzymes such as neprilysin, insulin degrading enzyme, and endothelin 
converting enzyme (Wang et al., 2010). 
3.1.2  Aβ aggregation and neurotoxicity 
Ab aggregation occurs through two pathways. One pathway involves the 
formation of low molecular weight oligomers without secondary structure 
(Hoyer et al., 2008) and subsequent formation of amorphous aggregates that do 
not convert into fibril (off-pathway, Fig. 3.2). On the pathway to fibrillation, the 
disordered monomer adopts a b-hairpin conformation as a constituent of soluble 
oligomers (Hoyer et al., 2008), which further form larger protofibrils (Harper et 
al., 1997, Walsh et al., 1997), and eventually undergo a structural 
interconversion into fibrils (Fig. 3.2). 
 
Figure 3.2 Illustration of Ab aggregation via the off- and on-pathway. Disordered monomer forms 
low molecular weight oligomers that lack a regular secondary structure, which enters the off-
pathway and remain as amorphous aggregate. On the on-pathway, disordered monomer first form 
b-hairpin structure which end up in fibrils through a dynamic intermediates state.  
Previously, much attention was given to fibrils found in the brain of AD patients. 
However, the role of fibrils in AD pathogenesis is debated. The plaque burden 
in AD brain does not correlate well with the degree of impaired memory and 
cellular dysfunction (Kayed and Lasagna-Reeves, 2013), and removing the 
plaque from the brain in an AD mouse model does not revert the observed 
dysfunctionality (Hardy, 2009). The focus of research has shifted from fibrils 
towards the soluble intermediate aggregates such as oligomers or protofibrils 
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(Walsh and Selkoe, 2007, Sengupta et al., 2016). It has become evident that these 
soluble oligomers do correlate well with the severity of disease (Lue et al., 1999, 
McLean et al., 1999), and are more toxic to neurons than the fibrils (Kuperstein 
et al., 2010, Benilova and De Strooper, 2013). A variety of soluble aggregates 
have been identified in vivo and in vitro ranging from dimers-tetramer (Shankar 
et al., 2008, Klyubin et al., 2008), pentamer and hexamers (paranuclei) 
(Roychaudhuri et al., 2009), and Ab*56 (Lesné et al., 2006). It is thought that 
the toxicity of soluble oligomers depends on the size of the Ab assemblies. An 
inverse correlation has been proposed between the size of soluble aggregates and 
the potency of their toxicity (Sengupta et al., 2016). Even the smallest oligomers 
i.e. dimers isolated from the cortex of AD brain were found to be toxic compared 
to dimers isolated from non-AD brain (Jin et al., 2011, Härd, 2011). However, 
much of the details about oligomer formation and toxicity remain elusive. New 
proteins that specifically recognize intermediate aggregates would be valuable 
tools in basic research as well as in diagnosis and therapeutics. In paper I of this 
thesis, new affinity proteins with selective binding capacity towards Ab 
protofibrils are developed. 
3.1.3  Studies of soluble Aβ aggregates 
The biochemical and biophysical studies of soluble Ab aggregates are very 
challenging due to the heterogeneity among aggregates and the high propensity 
of these aggregates to form fibrils. To control the various aggregates state (i.e. 
stabilize it), many methods have been developed including protein engineering, 
chemical cross-linking, and the use of mixed solvent or detergent (reviewed in 
Härd, 2011). 
In this thesis (paper I, III, and IV), protofibrils formed by an engineered 
version of Aβ peptide, called AβCC, are used. The AβCC model will be 
discussed in the section below. 
The AβCC protofibril—a mimic of wild type Aβ 
The Ab peptide is predominantly disordered, and does not adopt a unique 
conformation in solution. However, it has been demonstrated that the Ab peptide 
adopts a b-hairpin conformation (Hoyer et al., 2008). The structure of the Ab40 
peptide in complex with Affibody molecules (ZAb3; see the following section) 
was studied using NMR in which Ab was observed to adopt a b-hairpin 
conformation (Fig. 3.3a). The b-hairpin conformation was characterized by 
antiparallel b-stands formed by residues 17-23 and 30-36 and stabilized by 
intramolecular hydrogen bonds. The N-terminus of the Ab peptide was not well 
defined in the NMR spectra, and it has therefore been suggested to be disordered. 
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However, the secondary structure of the Ab peptide in Ab:ZAb3 complex 
resembled well with the Ab conformation in fibrils (Hoyer et al., 2008).  
 
Figure 3.3 a) The b-hairpin conformation of the Ab peptide (in gray) observed in complex with 
ZAb3 dimer (in green). b) (To the left) A b-hairpin conformation showing that the two alanine 
residues (Ala21 and Ala30) on opposite b-stands are in close proximate and were subjected to 
mutations. (To the right) Model of the AbCC variant in which Ala21 and Ala30 have been mutated 
to Cys21 and Cys30, which creates an intramolecular S-S bond (colored yellow), thereby locking 
the b-hairpin conformation. The 3D structure of Ab:ZAb3 complex was produced using PBD 
accession no. 2OTK and the structures in panel b was adapted from T. Härd. 
In a later study, two cysteines were introduced in the b-hairpin conformation, 
one at position 21 (A21C) and one at position 30 (A30C). These two cysteine 
residues form an intermolecular disulfide bond, which locks the b-hairpin 
conformation (Fig. 3.3b) (Sandberg et al., 2010). The double cysteine variant of 
the peptide is called AbCC. The AbCC form oligomers but not fibrils unless a 
reducing agent is added (Sandberg et al., 2010). It has been demonstrated that 
the protofibril formed by AβCC is a good mimic of wt-protofibrils as determined 
by a number of methods including, ThT fluorescence, TEM, AFM, circular 
dichroism, analytical ultracentrifugation, immunohistochemistry, cell toxicity, 
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and a structural model based on solid-state NMR and Rosetta modeling 
(Sandberg et al., 2010, Dubnovitsky et al., 2013, Lendel et al., 2014). 
 Affibody molecules—a class of engineered affinity proteins 
Until 30 years ago, it was believed that the immune system is the only source of 
affinity proteins i.e. antibodies, and remain a primary choice for the detection of 
specific antigen to this day. However, antibodies have some limitations such as 
their large size, production complexity, and cost, which has motivated 
researchers to develop of non-antibody proteins as an alternative. Affibody 
molecules are a kind of affinity proteins, which originated from an engineered 
domain called Z domain (see below) of staphylococcal protein A (SpA). SpA is 
located on the surface of Staphylococcus aureus cells and has five homologous 
IgG-binding domains, denoted as E, D, A, B, and A, that are capable of binding 
to the Fc region of antibodies from different species and subclasses (Moks et al., 
1986). The B domain was initially engineered with a few modifications to 
increase chemical stability towards hydroxylamine and to facilitate cloning, and 
the mutated domain was denoted Z domain (Nilsson et al., 1987). The Z domain 
is 58-residue (6.5 kDa) scaffold protein with three a-helices that form a bundle-
like structure. Its small size, high solubility and easy production, absence of 
internal cysteine residues, rapid folding kinetics, and high-affinity binding to 
targets convinced researchers to explore its potentials as future non-antibody 
affinity protein (Nygren, 2008). So-called Affibodies are the next generation of 
the Z domain. In 1995, the first Affibody combinatorial library was created by 
randomizing 13 solvent-exposed residues on helix 1 and 2 of the Z domain 
scaffold (Nord et al., 1995). After two years, in 1997, high-affinity proteins were 
isolated from the library using phage display technology (Nord et al., 1997). 
During the last two decades, Affibody-based proteins have been designed for 
numerous targets for use in a variety of applications including in bio-separation 
(Rönnmark et al., 2002, Hedhammar and Hober, 2007), as detection agents 
(Karlstrom and Nygren, 2001), as blocking agent or inhibitor (Jonsson et al., 
2009, Hoyer et al., 2008), and in vivo tissue imaging (Sorensen et al., 2014). 
The Affibody ZAb3 was selected targeting Ab40 peptide and demonstrated to 
bind Ab40 with high affinity with a KD of 17 nM (Hoyer et al., 2008, Hoyer and 
Härd, 2008). Moreover, ZAb3 acts as an amyloid inhibitor, and has been shown 
to inhibit Ab fibrillation by sequestering monomeric Ab from Ab aggregation 
solution (Hoyer et al., 2008, Luheshi et al., 2010). Furthermore, it has also been 
demonstrated that the ZAb3 dissociates pre-formed aggregates, albeit very 
slowly, by shifting the dynamic monomer-oligomer equilibrium (Luheshi et al., 
2010). In addition, the potency of ZAb3 to inhibit Ab aggregation and to reduce 
neurotoxicity has also been tested in vivo using a Drosophila fruit fly model of 
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AD (Luheshi et al., 2010). The proven potency of ZAb3 has made it an important 
research tool and has been used in many studies. For instance, the stable Ab 
protofibril (described in previous section) was developed by exploiting ZAb3:Ab 
complex. Besides Ab, ZAb3-based inhibitors have been developed for other 
amyloidogenic proteins e.g., the HI18 inhibitor against IAPP aggregation, which 
is involved in type II diabetes (Mirecka et al., 2016) and AS69 against AaSyn 
aggregation involved in PD (Mirecka et al., 2014). All studies mentioned above 
were performed by targeting non-aggregated species (soluble peptide). In paper 
I of this thesis, we have identified Affibody-based affinity proteins targeting the 
protofibrillar aggregates of Ab. 
3.1.4  Aβ-associated proteins and AD 
Studies of postmortem amyloid plaques have shown that several proteins e.g., 
a-1 antichymotrypsin (Abraham et al., 1988), agrin (Cotman et al., 2000), 
apolipoprotein E (apoE), clusterin and collagen, (Liao et al., 2004), heparin 
sulfate proteoglycan (Sandwall et al., 2010) and serum amyloid P (Kalaria et al., 
1991) are colocalized with Aβ. It is thought that Aβ interacts with other proteins 
in human biofluid, which may lead to Ab toxicity and the subsequent 
development of AD. An important part of the work presented in this thesis is 
focused on identifying the binding partners of soluble pre-fibrillar and fibrillar 
Aβ aggregates in human biofluid (papers III and IV). 
3.1.5  Diagnosis and treatment of AD 
Currently, no single test can confirm AD. Several clinical tests and assessments 
are usually conducted for diagnosis of AD. These tests include medical and 
family history, cognitive tests like mini-mental state examination (MMSE; the 
most commonly used test), physical and neurological examination to check 
overall neurological health, and blood test to rule out other potential causes for 
memory impairments and confusions (Alzheimer’s Association, 2018). At 
present, cerebrospinal fluid (CSF) biomarkers, reduced levels of Aβ42, and 
elevated levels of total tau and p-tau, have increasingly been used at clinical 
laboratory for diagnosis AD (Zetterberg and Blennow, 2013, Niemantsverdriet 
et al., 2017). Also, imaging techniques such as positron emission tomography 
(PET) is used in research settings and clinical trials. Advanced PET techniques 
can be used to detect the amount of Aβ plaque in the brain (Sehlin et al., 2016). 
However, AD can only be diagnosed with complete accuracy only after death of 
the patient through a brain autopsy to confirm the presence of amyloid plaques 
and neurofibrillary tangles. 
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Today no cure exists for AD. However, some symptomatic treatments are 
available that delay the disease symptoms. Currently, two drugs—cholinesterase 
inhibitors and memantine, are approved by the US food and drug administration 
(FDA). These drugs act by counterbalancing the neurotransmitter disturbances 
(Yiannopoulou and Papageorgiou, 2013). Cholinesterase inhibitors protects or 
delay the degradation of acetylcholine, an important chemical messenger, and 
are prescribed for mild to moderate AD case. For moderate to severe AD, the 
NMDA receptor antagonist memantine is used (McKeage, 2009). Treatments 
targeting the pathological entity/reason of disease, referred to as disease-
modifying treatments, are underway for AD where Ab is the prime target. Many 
of these treatments are currently at different phases of clinical trials. Approaches 
used in such treatments include anti-amyloid strategies, decreasing the 
production of Ab or rapid clearance by inhibiting b- or/and g-secretase or 
activating a- secretase, halt or prevent Ab aggregation by developing anti-
aggregating compounds, and removal of toxic Ab aggregates, by for instance 
using active and passive anti-amyloid immunotherapy (reviewed in refs. 
Yiannopoulou and Papageorgiou, 2013, Folch et al., 2018, Cummings et al., 
2018).  
3.2 Transthyretin amyloidosis  
The transthyretin (TTR) protein was discovered in the 1940s and was initially 
called prealbumin since it migrates ahead of albumin during protein gel 
electrophoresis (Kabat et al., 1942). Later the name was changed to transthyretin, 
a name that reflects its dual functionality—transportation of thyroxine and retinol 
in the circulation (Robbins, 2002). 
TTR is a homotetrameric protein with a molecular weight of 55 kDa, which 
is predominantly produced in the liver and released into the plasma (Felding and 
Fex, 1982). Additionally, a small amount of TTR is produced in the choroid 
plexus of the brain and released into CSF (Weisner and Roethig, 1983, Herbert 
et al., 1986). Also, the retina of the eye and the endocrine cells of the pancreatic 
islets are reported to be TTR production sites (Hamilton and Benson, 2001). In 
healthy individuals, the TTR tetramer functions as a transporter for thyroxin and 
retinol in plasma and CSF. However, mutations in the TTR can lead to a 
destabilization of the tetramer, which results in an increased propensity to 
aggregate and accumulate as amyloid in various organs. The aggregation-prone 
TTR protein is called ATTR, and the disease is called ATTR amyloidosis. 
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3.2.1  Structure of TTR 
The X-ray crystal structure of human TTR was solved in 1971 (Blake et al., 
1971), which revealed a structure with high b-sheet content. A native TTR 
monomer is composed of 127 amino acids and forms eight b-stands denoted A-
H and a small a-helical structure between E and F stands (Fig. 3.4a). The eight 
b-stands form two b-sheets, the b-stands D, A, G, and H form one b-sheet and 
the second b-sheet is formed by b-stands C, B, E, and F. The two b-sheets are 
organized face-to-face forming a b-barrel. Two monomers dimerize through 
intramolecular extensive hydrogen bonding between H-stands of each monomer. 
Hydrogen bonds between the F stands are also present, but to a lower extent with 
only one pair in the dimeric structure. The structure is further organized into a 
tetramer where two dimers interact through hydrophobic contact involving the 
loop region between b-stands A and B and b-stands G and H (Fig. 3.4b) 
(Hörnberg et al., 2000). Assembling two dimers into a tetramer in this manner 
provides a hydrophobic channel for thyroxin binding. Two thyroxin binding sites 
are available per tetramer (Fig. 3.4b). 
 
Figure 3.4 Cartoon presentation of TTR structure. (a) Self-assembly of two monomeric units (one 
colored green and the other gray) into dimer and (b) two dimers into a tetrameric functional unit. 
Thyroxin binding channel is indicated with dotted arrow. The structures were produced using PDB 
accession no. 1F41, a model structure of human wt-TTR solved using X-ray crystallography at 1.5 
Å resolution.  
3.2.2  ATTR fibrillation 
It has been well established that the TTR protein becomes aggregation-prone 
upon dissociation into partially unfolded monomer, which then rapidly self-
assemble into oligomers before forming insoluble fibrillar aggregates (Fig. 3.5) 
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(Foss et al., 2005). However, unlike the classical amyloid aggregation pathway 
(discussed in chapter 2.3), the ATTR aggregation occurs via a non-nucleated 
mechanism known as downhill polymerization (Hurshman et al., 2004). The 
dissociation of tetramer into monomers is the rate-limiting step in the 
aggregation process. Thus, seeding does not accelerate ATTR aggregation as 
demonstrated by in vitro kinetic data (Hurshman et al., 2004, Eisele et al., 2015). 
Nevertheless, a more recent study has demonstrated that patient-derived amyloid 
seeds accelerate monomeric and tetrameric TTR fibrillation in vitro (Saelices et 
al., 2018). Conditions that favor TTR dissociation and subsequent aggregation 
are debated. Some studies have shown that acidic conditions are required for 
tetramer dissociation and fibril formation (Lai et al., 1996, Lashuel et al., 1999), 
while others have demonstrated that the fibrillation can occur at physiological 
pH (Quintas et al., 1997, Quintas et al., 1999). 
 
Figure 3.5 Illustration of ATTR fibrillation, which is initiated by dissociation of native folded 
tetramer into monomer which are further converted into amyloidogenic monomer. Subsequently, 
the amyloidogenic monomer assembled into higher ordered aggregates en route to fibril. 
3.2.3  ATTR-derived amyloidoses 
ATTR amyloidosis exits in two main forms: hereditary ATTR amyloidosis 
(hATTR), which affects multiple organs e.g., peripheral nerves, heart, eyes and 
kidney and wild-type ATTR amyloidosis (ATTRwt), which primarily affects the 
heart. The hATTR is associated with mutations in the TTR genes and is a lethal 
autosomal dominant disorder. As of October 2018, 137 different mutations have 
been identified in the TTR gene (http://amyloidosismutations.com/attr.html). 
The most common TTR mutation globally is ATTRV30M (valine to methionine 
substitution at position 30), which is associated with hATTR with 
polyneuropathy. Another example on a polyneuropathy mutation is ATTRL55P, 
which is considered to be the most pathogenic variant (Lashuel et al., 1999) and 
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is associated with an early age onset (at about 15-20 years) polyneuropathy 
(Jacobson et al., 1992). 
The ATTRV122I mutation, which is frequently found among individuals of 
African descent (Jacobson et al., 1996), and the ATTRL111M mutation, which 
is common in the Danish population (Nordlie et al., 1988), are two examples of 
hATTR with cardiomyopathy. 
In old age, the wt-TTR can also forms amyloid (Cornwell et al., 1988, 
Westermark et al., 1990). In approximately 25% of all individuals above the age 
of 80 years, some cardiac amyloid deposit composed of wt-TTR can be detected 
(Westermark et al., 1990, Tanskanen et al., 2008). 
3.2.4  Diagnosis and therapies for ATTR amyloidosis 
Commonly, tissue biopsy followed by Congo red staining is used for the 
identification of amyloid in tissue and typing of amyloid deposit is most 
commonly performed by western blot or mass spectrometry (Suhr et al., 2000). 
During this procedure, a small piece of subcutaneous fat tissue (sometimes from 
other sites) is used as smear and subjected to Congo red staining. When amyloid 
is present, this is detected as an apple-green birefringence under a polarized 
microscope. However, Congo red staining is reliant on the size of the aggregates 
that can be detected, and therefore small aggregates could be overlooked. In 
paper II of this thesis, we attempted to develop an assay for detection of early 
ATTR deposits. 
Previously, liver transplantation (LT) was thought of as the first-line 
treatment for hATTR amyloidosis. In LT treatment, the mutant ATTR producing 
liver is replaced by a wt-TTR producing liver (Suhr et al., 2000). However, LT 
is limited by the availability of organs.  
The fact that tetrameric TTR needs to dissociate into monomer prior to the 
formation of amyloid, many drugs have been developed to stabilize the tetramer 
or halt dissociation and thereby prevent TTR amyloid formation. Notably, two 
drugs—diflunisal and tafamidis, have shown promising results in clinical trials. 
Tafamidis has been approved for treatment of hATTR amyloidosis in European 
countries and Japan (Sekijima, 2015) and has recently completed a phase II/III 
trials (Maurer et al., 2018). Structural studies demonstrated that tafamidis binds 
to the thyroxin binding sites (TTR dimer-dimer interface, see in Fig. 3.4) of the 
tetramer and in this way stabilizes the two dimeric species into tetramer (Bulawa 
et al., 2012). Other promising therapeutics on the way are antisense 
oligonucleotides (Benson et al., 2017) and siRNAs (Rizk and Tuzmen, 2017) for 
suppression of mutant and wt-TTR synthesis. These drugs are currently in phase 
III trials. 
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Nonpathogenic amyloid structures are ubiquitous in Nature. Numerous 
organisms including bacteria, fungi, insects, and mammals—including humans, 
utilize amyloid structures for a diverse range of biological functions. The current 
chapter will discuss the examples of natural amyloid as well as the potentials of 
amyloid for artificial functional materials. 
4.1 Beneficial formation of amyloid in Nature 
The discoveries of functional amyloid in yeast have changed the way we 
perceived amyloid. Of the many cases known, the Sup35p and Ure2p proteins, 
both from Saccharomyces cerevisae, are well-studied amyloid structures in yeast 
(reviewed in ref. Chien et al., 2004). The Sup35p in its non-amyloid form 
functions as a translation termination factor that mediates the termination of 
protein synthesis at stop codons. However, the aggregation of Sup35p into 
amyloid disrupts its function and the protein no longer acts as a translational 
terminator. Thus, the translation continues through the stop codon, and this is 
thought to be associated with introduction of new phenotypes (Serio and 
Lindquist, 1999). In addition, it has been demonstrated that the formation of 
Sup35 fibrils allow yeast cells to withstand both heat and chemical stress better 
than yeast cells that do not contain Sup35 amyloid (True and Lindquist, 2000). 
This suggests that the conversion of Sup35p into fibrils in yeast cells may be the 
results of evolutionary selection (Lancaster et al., 2010). Like Sup35p, the Ure2p 
protein can also form amyloid. In its soluble form, Ure2p regulates nitrogen 
catabolism by repressing the activity of transcription factor Gln3p, which 
controls the expression of nitrogen catabolic gene DAL5 (Coffman et al., 1994). 
In the presence of a good nitrogen source, yeast blocks the expression of DAL5 
(Chien et al., 2004). The conversion of Ure2p into amyloid form prevent this 
action, which causes constitutive activation of Gln3p, and thus upregulation of 
4 Beneficial roles of amyloid 
 
 
36 
DAL5, which enables yeast to utilize poor nitrogen sources through pathways 
controlled by DAL5. 
Functional amyloids have also been discovered in gram-negative bacteria 
such as E. coli and Pseudomonas. Curli fibril, assembled from the protein CsgA, 
is a type of functional fiber believed to constitute the major proteinaceous 
component of the extracellular matrix produced by E. coli. (Arnqvist et al., 
1992). The assembly of curli fibril is tightly controlled and assisted by several 
co-factors such as CsgB, which favors the nucleation process, and CsgG, which 
transports CsgA to the extracellular space. Curli fibrils are thought to be 
involved in a range of activities including colonization of inert surfaces and 
biofilm formation (Vidal et al., 1998), and mediate binding to the host proteins 
(Olsén et al., 1993). 
Before the discoveries of these functional amyloid structures, amyloid found 
in human were thought to be associated with diseases only. Therefore, the 
identification of functional amyloid in humans, such as Pmel17 and various 
peptide hormones in secretory granules of endocrine system, has forced us to re-
evaluate how we look at amyloid. The Pmel17 has been demonstrated to catalyze 
melanin biosynthesis in melanosomes (Fowler et al., 2006), and storage of 
peptide hormones in pituitary secretory granules as aggregates are believed to 
play critical role in the regulation of their release (Maji et al., 2009). Table 4.1 
presents a selection of functional amyloid structures that occur in Nature for 
various physiological functions. 
Table 4.1 Examples of amyloid-like structure in natural use. 
Species Protein Physiological function of resulting fibril  
Bacteria   
Escherichia coli CsgA Curli fibrils involved in biofilm formation 
Pseudomonas FapC Fibrils in biofilm 
Streptomyces coelicolor Chaplins Modulation of water surface tension 
Fungi   
Saccharomyces cerevisae Sup35p New phenotypes by enabling stop codon read-through 
 Ure2p Enables yeast to uptake poor nitrogen source 
Animalia   
Insect and fish Chorion Structure and protection of the eggshell 
Nephila clavipes Spidroins Formation of silk fiber of the web  
Homo sapiens Pmel17 Catalyzes synthesis of melanin  
Table adapted from refs. Fowler et al., 2007, Knowles and Mezzenga, 2016. 
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4.2 Functionalization of amyloid 
The mechanical robustness, as well as the fact that amyloids are used in Nature, 
makes these structures attractive as the building block for artificial functional 
materials known as nanofibril-based material. The amyloid fibril-forming 
protein can be engineered as a fusion comprising functional biomolecules such 
as enzymes, antibody-binding domain, and metal-binding peptide. The fibril-
forming protein will spontaneously self-assemble to form nanofibrils with 
desired functionalities. Numerous of nanofibril-based materials have been 
developed for various applications in the field of biotechnology, medicine, and 
biomaterial sciences. For examples, nanofibril-based materials have been 
designed for use as cell culture scaffolds (Kasai et al., 2004, Gras et al., 2008), 
as vehicles for drug delivery (Silva et al., 2013), for capturing carbon dioxide 
from the environment (Li et al., 2014), and as efficient biosensors (Sajanlal et 
al., 2011, Hauser et al., 2014). A selection of fibril-forming proteins and their 
emerging applications are listed in Table 4.2. 
Table 4.2 Examples of emerging application of non-pathological and pathological amyloid fibril.  
Fibril protein Emerging applications 
β-lactoglobulin Biosensor, catalysis, hybrid, transfection, nanocomposites 
Lysozymea Artificial bones, hybrids, cell scaffolds 
Sup35p Biosensors, hybrids 
α-synucleina Hybrids, sensors 
CsgA/E. coli Curli  Under water adhesives 
TTR1a Cell scaffolds 
Ab42a Light harvesting, cell scaffolds, cell differentiation 
aalso form pathological deposit in human disease 
Table adapted from Knowles and Mezzenga, 2016. 
A functionalized nanofibril that has a high binding capacity to antibodies 
(hereafter called Ab-bNF for antibody-binding nanofibril), was recently 
assembled in our research group (Schmuck et al., 2017). The Ab-bNF is used in 
paper II of this thesis. The composition and efficiency of the Ab-bNF will briefly 
be discussed below. 
4.2.1  Antibody-binding nanofibrils 
In the Ab-bNF, fibrils formed from the N-terminal fragment (1-61) of Sup35 are 
exploited as frame for displaying the antibody-binding functional Z-domain 
(introduced in chapter 3.1.3). The Ab-bNF was assembled by co-fibrillation of 
the functional antibody-binding domain fused to the fibril-forming protein 
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(Sup35(1-61)-ZZ, chimeric protein) with fibril-forming protein alone (Sup35(1-
61), carrier protein). An optimized ratio between the chimeric and carrier 
proteins provided adequate space on the surface of the fibrils, which reduce 
steric hindrance, and thus maximizes the functionality of the Ab-bNF. The Ab-
bNF assembled using a molar ratio of carrier protein to chimeric protein of 
1:0.33 has a binding capacity of 1.8 mg antibody per mg Ab-bNF, which is 
almost 20-fold higher binding capacity compared to the gold standard Protein A 
Sepharose used for antibody purification (Schmuck et al., 2017). 
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5.1 Scope of this thesis  
This thesis focuses on two aspects: detection of Aβ and ATTR aggregates in 
vitro and ex vivo, and investigation of potential interactions of protofibrillar and 
fibrillar aggregates of Aβ with proteins in biofluid. 
 
Specific aims 
 
Paper I: to identify new affinity proteins that specifically bind to Aβ 
protofibrils. 
 
Paper II: to devise a method with high sensitivity for detection of TTR in 
vitro and ATTR deposits in tissue samples. 
 
Paper III: to investigate potential interactions between Aβ protofibrils and 
proteins in human serum and cerebrospinal fluid. 
 
Paper IV: to explore differences of binding profiles of cerebrospinal fluid 
proteins to protofibrillar and fibrillar aggregates of Aβ. 
5.2 Methodological considerations 
This section aims to highlight main methods as well as methods developed in 
the course of the thesis work. Details of experimental procedures used in each 
paper are described in the methods section of the corresponding paper. 
 
5 Present investigations  
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5.2.1  Surface plasmon resonance (paper I, III and IV) 
Surface plasmon resonance (SPR)-based biosensors provide a real-time and 
label-free technique to study biomolecular interactions (Jonsson et al., 1991). In 
this method, one binding partner is immobilized on a gold coated surface of a 
sensor chip while the other interacting-partner is injected in a continuous flow 
of solution. Polarized light is directed to the under surface of the gold film where 
surface plasmon is generated at a critical angle (resonance angle) of the incident 
light. Binding or dissociation of biomolecules at the sensor surface changes the 
local refractive index and produces a shift in the resonance angle (Schuck, 1997). 
The SPR provides more comprehensive information of the interactions between 
two molecules in terms of affinity, kinetics, concentration, and thermodynamics 
compared to other techniques such as isothermal calorimetry (ITC) and bio-layer 
interferometry (BLI). ITC cannot provide kinetic (association and dissociation 
constant) while BLI has very low sensitivity. 
The SPR experiments presented in this thesis were executed on a Biacore 
X100 system (GE Healthcare). The ligands, Aβ42CC protofibrils or Aβ42 fibril, 
were immobilized separately onto CM5 sensor chips (GE Healthcare) using 
standard amine coupling chemistry. Selected proteins were allowed to pass over 
the immobilized chip surface, and the association and dissociation of the binding 
kinetics were recorded. Collected data was fitted to 1:1 binding kinetic model or 
heterogeneous binding model with two binding sites. 
5.2.2  Immunoassay (paper II) 
We have developed an enhanced detection method to be used for the detection 
of small amounts of ATTR aggregates. The method is based on the Ab-bNF 
(introduced in chapter 4.2.1). An enhanced signal in an amyloid detection system 
can be achieved if an increased number of antibodies can be linked to the antigen 
avoiding steric hindrance. Using the Ab-bNF, whose surface contains the 
antibody-binding Z domain (Fig. 5.1a), we could increase the concentration of 
primary antibody in close association to the antigen, which then provides an 
increased number of binding sites for the secondary antibody that results in 
signal amplification (Fig. 5.1b). 
Anti-human TTR polyclonal (1899) antibody produced in rabbit was loaded 
onto the Ab-bNF by incubation at room temperature for 45 min. 1.8 µg antibody 
was added to per µg Ab-bNF. Hereafter the TTR antibody (1899) bound Ab-
bNF is referred to as TTR-bNF. After incubation, TTR-bNF was pelleted and 
washed to remove unbound antibodies followed by dilution in 1´ phosphate 
buffered saline prior to addition to microplate well containing TTR or on tissue 
section containing ATTR aggregates. The detection procedure was similar to 
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that of conventional microplate immunoassay or the immunolabeling of tissue 
section. Goat anti-rabbit antibody conjugated with Alexa Fluor 488 (GAR-Alexa 
488) (Thermo Fisher) was used for the detection of TTR-bNF bound to TTR or 
ATTR aggregates in tissue section. 
 
Figure 5.1 Concept of signal enhancement using Ab-bNF. (a) Anti-human TTR polyclonal (1899) 
antibody was bound to Ab-bNF via Z domain displayed on the surface, and (b) incubated with TTR 
antigen, the additional antibodies on the fibril surface amplify the number of secondary antibody 
binding sites thereby enhancing the signal. 
An advantage with this enhancement method is that it links many antibodies to 
the same binding site on the antigen, which increases the signal from the same 
antigen compared to the signal from a conventional immunoassay and thereby 
offer a more sensitive system for the detection of small pathogenic aggregates. 
A disadvantage of this method is that it requires a large amount of antibody 
compared to conventional method. However, method development is still at an 
early stage, and this obstacle should be included in the further optimization 
strategies. 
5.2.3  Protein pull-down assay (paper III and IV) 
We established a protein pull-down assay to investigate the potential binding of 
Aβ protofibril and fibril to proteins in serum and CSF. Previously, affinity 
chromatography-based method was developed for this purpose (Calero et al., 
2012). This method involved in preparation of affinity matrix by preincubation 
of Aβ with activated cyanogen bromide (CNBr) sepharose and subsequent 
packing a chromatography column with the matrix. The sample of interest was 
run over the column, and bound proteins were eluted. A similar approach was 
demonstrated by Medvedev et al. using a different sepharose matrix, i.e. Aff-
Gel10 (Medvedev et al., 2015). However, these protocols are time-consuming 
and require expensive instruments such as a liquid chromatography system. 
Moreover, the volume of the eluate from this setup is large and often needs to be 
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concentrated for downstream analysis, which increases the risk of losing 
material in the process. We developed a simple capturing assay which does not 
require expensive instruments and can be performed in an Eppendorf tube. The 
other strength of this assay is that the elution volume can be limited to a few µL. 
 
Figure 5.2 Illustration of the pull-down assay used to investigate the binding of serum and CSF 
proteins to protofibrillar and fibrillar aggregates of Aβ. (a) Aβ aggregates were coupled onto the 
Dynabeads M-280. (b) Bead-Aβ complex was incubated with serum or CSF samples for protein 
binding (b.i). (c) Proteins bound to Aβ were eluted by heating in SDS-PAGE sample buffer. 
We used M-280 magnetic Dynabeads (Invitrogen, catalog #14204) as matrix for 
coupling the ligands i.e. Aβ aggregates. The bead surface contains activated 
tosyl groups, which bind to amino groups of the ligands by formation of amine 
bonds. The bead is ideal for coupling ligands containing primary amino group 
and has high coupling efficiency. The ligands (Aβ42CC protofibril or Aβ42 fibrils, 
100 µg) were incubated with 5 mg beads in 0.1 M Na-phosphate at pH 7.4 
overnight at 37 °C for covalent binding, followed by an additional 1 h incubation 
in PBS pH 7.4 with 0.5% Tween-20 to block remaining binding sites on the bead 
surfaces. After this process, the bead-Aβ complex is ready to study its interaction 
with proteins in serum or CSF (Fig. 5.2a). For capturing Aβ-binding partners in 
serum or CSF, bead-Aβ complex (0.5 mg) was incubated with serum (150 µL) 
or CSF (200 µL) at 37 °C for 1h (Fig. 5.2b,bi). Beads were then washed 
rigorously three times, and bound proteins were eluted in 12 µL SDS-PAGE 
sample buffer (Bio-Rad) by heating at 70 °C for 10 min (Fig. 5.2c). 
The pull-down assay was further accompanied by LC-MS/MS identification 
of bound proteins and SPR biosensor-based validation of binding.  
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In the following sections of this thesis, the work in the appended published 
papers and manuscript are reviewed. Paper I and II are presented separately, and 
then the paper III and IV are presented together. Conclusions follow each of 
these reviews. The chapter ends with general discussion and possible future 
directions of this thesis work. 
5.3 New affinity proteins to detect Aβ protofibrils (paper I) 
The field of AD research is in great needs of potential methods to detect and 
distinguish soluble Aβ protofibril from other aggregated forms and monomer. 
However, antibodies targeting pre-fibrillar Aβ have previously been developed 
(Kayed et al., 2003, Englund et al., 2007, Kayed et al., 2007). This study focuses 
on in vitro development of new affinity protein, alternative to antibodies, to 
detect Aβ protofibrils. 
5.3.1  Selection and validation 
Affibody-based affinity proteins were selected by phage display selection 
(Gronwall et al., 2007). Protofibrils formed from Aβ42CC variant were used as 
target molecules in the selection method. Six rounds of selection and phage 
amplification were performed. For the post-selection screening, 744 randomly 
chosen colonies were expressed directly from phagemid vector in fusion to an 
albumin binding domain (ABD) and screened for binding to Aβ42CC using an 
enzyme linked immunosorbent assay (ELISA). Twenty-five potential 
candidates, EC50 values in the range of 15 to 90 nM, were identified and among 
these the five most promising binders were denoted as ZAβ42cc_1, ZAβ42cc_2, 
ZAβ42cc_3, ZAβ42cc_4, and ZAβ42cc_5 (hereafter collectively called Abpf-binders) 
were considered for further characterization. 
These top five binders were then tested for their selective binding to 
protofibrils over other forms of Ab. Aβ42wt protofibrils were also included in 
this experiment. ABD-fused Abpf-binder was immobilization on ELISA plate 
via an anti-ABD antibody followed by incubation with various form of Ab. To 
detect bound Ab to Abpf-binder, conformation independent monoclonal 
antibody 6E10, or conformation-specific antibody mAb1C3 (has some 
specificity for Aβ42 protofibrils (Englund et al., 2007)) were used. 
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Figure 5.3 Selective binding of the top five Abpf-binders to various forms Aβ tested by ELISA 
using monoclonal antibody 6E10 (a) and mAb1C3 (b). A non Aβ-binder Affibody molecule, 
ZTaq_2, PBST, and PBST replacing antibodies were used as controls. Values are means of 
duplicate experiments. 
As shown in Figure 5.3, all tested Affibody molecules bound well to Aβ42CC 
protofibrils, and none of them bound to either monomer or fibrils. Moreover, 
incubation with 6E10 showed that ZAβ42cc_1 also bind to Aβ42wt protofibrils 
(Fig. 5.3a). Notably, the conformation-specific mAb1C3 experiment revealed 
that not only ZAβ42cc_1, but also ZAβ42cc_3 and possibly ZAβ42cc_4 bound to wt-
protofibrils (Fig. 5.3b). Why the two other Abpf-binders i.e., ZAβ42cc_2 and 
ZAβ42cc_5 did not recognize the wt-protofibrils can be explained by the fact that 
the wt-protofibrils might form mature fibrils during 1 h incubation time and 
washed off before detection. The interconversion of wild-type protofibrils to 
mature fibrils happens rapidly (Luheshi et al., 2010). The situation can also be 
true for the experiment where 6E10 antibody is used (Fig. 5.3a). 
a
b
0
0.1
0.2
0.3
0.5
0.4
0.6
0.7
ZAβ42cc_1 ZAβ42cc_2 ZAβ42cc_3 ZAβ42cc_4 ZAβ42cc_5 ZTaq_2 PBST ZAβ42cc_1 
(-6E10)
Aβ42cc-protofibril
Aβ42wt-monomer
Aβ42wt-protfibril
Aβ42wt-fibril
Blank
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
ZAβ42cc_1 ZAβ42cc_2 ZAβ42cc_3 ZAβ42cc_4 ZAβ42cc_5 ZTaq_2 PBST ZAβ42cc_1 
(-1C3)
Aβ42cc-protofibril
Aβ42wt-monomer
Aβ42wt-protfibril
Aβ42wt-fibril
Blank
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
ZAβ42cc_1 ZAβ42cc_2 ZAβ42cc_3 ZAβ42cc_4 ZAβ42cc_5 ZTaq_2 PBST ZAβ42cc_1 
(-1C3)
Aβ42cc-protofibril
Aβ42wt-monomer
Aβ42wt-protfibril
Aβ42wt-fibril
Blank
6E10
mAb1C3
 
 
45 
An affinity capture assay with shorter incubation time was then carried out. 
This assay involved immobilization of Abpf-binder on nickel-charged resin 
employing a His6 tag followed by 5 min incubation with various Aβ species. 
SDS-PAGE analysis confirmed the selective binding of Abpf-binder to 
protofibrils over other species (Fig. 5.4a). The results suggest that the tested 
binders (ZAβ42cc_1 and ZAβ42cc_4), recognized Aβ42wt protofibrils and Aβ42CC 
protofibrils with similar selectivities/intensities (Fig. 5.4b), which was the 
expected outcome of this experiment. 
 
Figure 5.4 (a) Representative SDS-PAGE analysis of the samples obtained from affinity capture 
assay using ZAβ42cc_4 as ligand. Aβ species that bind to ZAβ42cc_4 are eluted together with ZAβ42cc_4 
(indicated as bound to Aβ) and Aβ species that did not bind to ZAβ42cc_4 are recovered in supernatant 
(indicated as non-bound to Aβ). The band corresponding to Affibody and Aβ are indicated by arrow 
head. (b) SDS-PAGE band intensities corresponding to bound and non-bound Aβ. The data was 
normalized with respect to each Aβ species, i.e. the sum of the intensities for bands originating 
from one Aβ species is equal to 100%. 
5.3.2  Binding kinetics of Aβpf-binders to protofibril 
All tested Abpf-binders showed low nanomolar (nM) binding affinity1 to 
Aβ42CC protofibrils, determined by SPR. Average dissociation constants, KD, 
                                                        
1. Kinetic data can be found in Table S1 in the supplementary information of paper I 
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were determined to be ≈1.7 (±0.6) nM. However, in order to detect Ab 
protofibrils in biological samples, for instance in CSF, even stronger binders are 
required. The concentration of protofibrils in the AD CSF is in the picomolar 
range (Georganopoulou et al., 2005), while in the brain of AD patient the 
concentration has yet to be determined but is presumed to be very low. Using 
conformation-specific antibodies, efficient capture of Ab protofibrils with 
concentration in the picomolar range was demonstrated previously (Englund et 
al., 2007, Yang et al., 2015). 
A recent study had shown that the affinity of the Affibody molecules to a 
protein containing multiple similar binding surfaces (Ab protofibril might have 
such surfaces) can be improved 1000-fold by making dimeric construct 
(Lindborg et al., 2013). We therefore constructed 14 dimers and studied their 
binding to Aβ42CC protofibrils by SPR. However, the affinity improvement with 
dimeric construct was not as great as expected. All dimeric Abpf-binders showed 
either equal or up to one order of magnitude stronger affinity compared to the 
monomers. Further studies, in particularly, structural comparisons of monomeric 
and dimeric constructs as well as the surface on protofibrils, would be required 
to understand why higher affinities are not achieved with dimeric construct. 
5.3.3  Binding topology 
Mapping of the chemical properties of selected side chains onto the Abpf-
binders revealed three chemically distinct regions of the Z-domain surface as 
positive-nonpolar-polar. The surface pattern of Abpf-binders presumably 
matches a corresponding surface epitope on the protofibrils. In fact, a recently 
developed structural model of protofibril contains surfaces that appear to match 
the selected Affibody molecules (Lendel et al., 2014). However, further 
structural studies are required to confirm the binding site on the protofibrils. 
5.3.4  Conclusions 
In this study, we have identified Affibody-based potential proteins that 
specifically recognize and bind Aβ42CC protofibrils. Importantly the binders 
also recognize protofibrils formed by Aβ42wt peptide. The binders have potential 
to be used for detection of Aβ42 protofibril over other aggregated forms and 
monomer both in research as well as diagnostics and therapeutic applications. 
Future work should be devoted to extensive characterization of these 
binders—in particular structural studies to get insight into the structural basis for 
the interactions with protofibrils. It would also be relevant to investigate the 
potential of these affinity proteins in brain imaging. Another exciting future 
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study would be designing a new functional Ab protofibril-binding protein 
nanofibril, where the Ab-pf binder will be displayed on the fibril surface, a 
similar strategy used in paper II. 
5.4 Development of method for sensitive detection of 
ATTR aggregates (paper II) 
The tissue damage caused by amyloid deposition is not repairable, and early 
detection of amyloid deposit can provide early treatments thus prevent 
progressive tissue damage. In this study, we improved an ATTR detection 
system by exploiting nanofibril functionalized with TTR antibody (TTR-bNF) 
to detect small amount TTR amyloid. 
5.4.1  Signal enhancement in microplate immunoassay 
To test the efficacy of the TTR-bNF, we performed a microplate immunoassay 
using a stable monomeric TTR (mono-TTR) (Jiang et al., 2001), as antigen. The 
mono-TTR was immobilized onto the microtiter plate well. TTR-bNF charged 
with ≈13.5 µg anti-human TTR polyclonal (1899) antibody was added to the 
well. After incubation, TTR-bNF bound to mono-TTR was detected using GAR-
Alexa 488. In parallel, a reference assay was performed using the same 
procedure except that 1 µg antibody was added to wells with no fibrils included. 
Using the improved assay, sensitivity was enhanced 128-fold compared to 
the reference assay (Fig. 5.5a). A control experiment that involved 
immobilization of mono-TTR onto a microtiter plate wells followed by 
incubation with increasing concentration of primary antibody showed that 
fluorescence could not be increased by adding more antibody without loading 
onto the fibrils (Fig. 5.5b). This demonstrated that the enhanced signal is due to 
TTR-bNF in the system. 
The results showed that the concept for signal enhancement worked as 
expected. However, the current protocol has limitations. For example, the limit 
of detection cannot be precisely calculated from the collected data using the 
current setup due to the large standard deviation that was observed. Possible 
reasons for the large standard deviation could be the diversity of the fibril lengths 
as well as longer fibrils employed in the assay. The use of a uniform fibril length 
could be critical, since it determines the number of primary antibodies 
introduced into the system. In addition, longer fibrils are heavier and could be 
more susceptible to uncontrolled release from the surface due to shearing forces 
during the washing steps. The irregular data points in our assay support this 
hypothesis. Our Ab-bNFs are quite long and exhibit fibrils of diverse lengths 
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ranging from 1-2.4 µm analyzed by TEM. Another factor that possibly 
contribute to the large variation between data points is uneven distribution of 
fibril in solution. 
 
Figure 5.5 Signal enhancement in microplate immunoassay. (a) Comparison of TTR-bNF assay 
(green) with reference assay (black) (b) A plot showing that the florescence cannot be increased by 
adding extra amount of antibody if they are not loaded onto fibrils. Each data point represents mean 
± SD (n=3). 
 
Introduction of shorter fibrils of ca. 500 nm into the system could prevent 
uncontrolled release from surface and also minimize the uneven distribution in 
the solution, as demonstrated in a previous study (Men et al., 2009). Fibrils with 
shorter length can be produced by adding more seeds during fibril assembly. 
Also, a relatively large volume of fibrillation solution (than the amount used) 
can be beneficial to produce small fibrils as well as their even distribution in the 
solution. In addition, the strategic testing of the fibril compositions i.e. different 
ratios of fibril-forming proteins (Sup35) and fusion protein (Sup35-ZZ) should 
be performed. Importantly, the reproducibility of the Ab-bNF should be a key to 
obtain the defined fibrils lengths and fibrils distribution. 
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5.4.2  Enhanced signal in immunolabeling of ex-vivo tissue 
Next, we tested the usefulness of the method in immunolabeling of patient-
derived tissue containing ATTR aggregates. This assay involved incubation of 
tissue section with TTR-bNF containing either 9 µg or 13.5 µg primary antibody 
followed by detection of bound TTR-bNF using GAR-Alexa 488. For 
comparison, decreasing concentrations of primary antibody, 1 µg, 0.5 µg or 0.25 
µg was directly added to the section. 
 
Figure 5.6 Enhanced fluorescence in immunolabeling of patient-derived tissue containing ATTR 
aggregates using the TTR-bNF. Top two images, the regular assay where primary antibody was 
directly added to the tissue sections. Bottom two images, the TTR-bNF assay where primary 
antibody was bound to the fibrils before addition to the tissue sections. 
As shown in Figure 5.6, amyloid specific signal was observed in section 
incubated with 0.25 µg of antibody. In comparison the section incubated with 1 
µg (4-fold more) antibody exhibited a weaker signal, which is not uncommon 
when tissue section is incubated with higher antibody concentration. As 
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expected, section incubated with TTR-bNF carried 9 µg antibody, which is 
almost 10-fold more antibodies compared to above reference, results in strong 
fluorescent signals. Notably, much stronger signal is observed in section 
incubated with TTR-bNF that carried 13.5 µg antibody compared to signal 
observed in section incubated with TTR-bNF that carried 9 µg antibody (Fig. 
5.6, bottom images). This result shows that the enhanced signal is indeed due to 
TTR-bNF. Moreover, the enhanced signal is well associated with amyloid 
deposit in tissue, and the unspecific binding of amyloid fibril (TTR-bNF) to the 
tissue could be excluded. The result indicates that the method has potential to 
detect small aggregates deposited in tissue, and further evaluation should be 
performed on tissue with very small amyloid deposits. 
5.4.3  Conclusions 
The results produced in the pilot study are promising, but further optimizations 
are warranted. With further development the detection system could provide a 
new method for the detection of small amyloid aggregates. Currently, we are 
focusing on producing short fibrils with uniform length. 
Interesting future studies would be to explore the method in the detection of 
other amyloid aggregates such as Ab and IAPP aggregates. 
5.5 Identification of Aβ interactome in biofluid (paper III 
and IV) 
Numerous proteins are colocalized with Aβ in the AD plaque, and may associate 
with soluble Aβ in CSF and serum. Identification of Aβ-interacting partners in 
serum and CSF is of great interest for studying Aβ-related neurotoxicity in AD 
as well as biomarker discovery. Potential binding partners of pre-fibrillar and 
fibrillar form of Ab in serum, and AD and non-AD CSF is investigated in paper 
III and IV. 
5.5.1  Aβ sequesters numerous proteins in biofluid 
We identified a couple of hundred proteins that bound to various forms of Aβ. 
In paper III, we studied the binding of serum proteins to Aβ42CC protofibrils. 
The binding partners of Aβ42CC protofibrils in serum were captured using the 
pull-down assay outlined the chapter 5.2.3. The MS analysis of the captured 
proteins revealed that 51 different proteins bound to Aβ42CC protofibrils from 
serum. Beads coated with glycine were used as control. A few proteins were 
found to bind the control beads, but the binding level was low (Fig. 5.7), which 
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was further confirmed by the peptide abundance indices (PAI) values (Sanders 
et al., 2002). 
 
Figure 5.7 An SDS-PAGE analysis of protein samples extracted from serum using Aβ42CC 
protofibril- and glycine-coated breads showing that more proteins are extracted by beads coated 
with Aβ42CC protofibril than beads coated with glycine. The arrows indicate bands corresponding 
to Aβ42CC monomer (M), dimer (D), and trimer (T). 
CSF is perhaps more biologically relevant to AD pathology (Blennow et al., 
2010) compared to serum. We studied the binding of CSF proteins to Aβ42CC 
protofibrils (paper III) and Aβ42wt fibrils (paper IV). Of twelve CSF samples 
used, six were from AD and six from non-AD patients (see Table 5.1 for the 
clinical features of CSF sample). 
Table 5.1 Patient characteristics and CSF parameters. Patients were designated as AD or non-AD 
as previously described (Hansson et al., 2006). 
 n M/F (n) Age (y) Aβ42 (ng/L) t-tau (ng/L) p-tau (ng/L) 
non-AD 6 1a/3 71.2 ± 7.1b,c 808.5 ± 253.7 262.7 ± 145.9 40 ± 17.8 
AD 6 3/3 65.8 ± 8.7 454 ± 140.2 782 ± 94.4 93.1 ± 11.3 
atwo samples without recorded gender. 
btwo samples without recorded age. 
cCalculated for four samples. 
non-AD, non-Alzheimer’s disease; AD, Alzheimer’s disease; t-tau, total tau; p-tau, phosphorylated tau 
Values are expressed as mean ± SD. 
 
Like the serum experiment, several proteins were extracted by both Aβ42CC 
protofibril- and Aβ42wt fibril-coated beads from CSF samples. Also, the same 
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(Fig. 5.8). Through the MS analysis we identified 74 and 201 proteins2, extracted 
by Aβ42CC protofibril- and Aβ42 fibril-coated beads from CSF, respectively. 
However, while comparing Aβ42CC protofibrillar binding proteins with Aβ42wt 
fibrillar binding proteins, the Aβ42wt fibril-binding proteins list were corrected 
by subtracting3 proteins below 20 kDa and above 250 kDa (56 proteins 
subtracted4) which results the number of Aβ42wt fibril-binding proteins to 145. 
These numbers show that more proteins are extracted by Aβ42 fibril-coated beads 
than beads coated with Aβ42CC protofibril. Notably, many proteins were 
identified to bind Aβ42wt fibril but not Aβ42CC protofibrils. Hence, we called 
these Aβ42wt fibril-specific proteins (paper IV). 
 
Figure 5.8 Representative SDS-PAGE analyses of protein samples extracted from CSF by Aβ42CC 
protofibrils, glycine, Aβ40wt monomer, tryptophan, and Sup35 fibrils coated beads. More proteins 
bind to Aβ42CC protofibril-coated beads than beads coated with glycine, Aβ40wt monomer, and 
tryptophan. Protein binding pattern to Sup35 fibrils is different compared to binding to other tested 
samples. Arrow heads indicate bands corresponding to Aβ42CC monomer (M), dimer (D) and trimer 
(T), and Sup35 (S35). 
Substantial variation of protein binding among the CSF samples were noted. 
Such differences are expected due to heterogeneity among the CSF samples. The 
number of identified proteins did not show obvious correlation with total protein 
content or sex. However, a positive correlation between age and the number of 
                                                        
2. The complete list of protofibril-binding proteins can be found in Supporting Information S1 
of paper III, and fibril-binding proteins are found in Supporting Table S1of paper IV. 
3. The rationale for this subtraction is, in the protofibril-binding experiment, the pull-down eluate 
was run on SDS-PAGE and proteins migrating between the MW of 20-250 kDa were cut out 
and analyzed by LC-MS/MS, whereas, in the fibril-binding experiment, the whole eluate was 
subjected to LC-MS/MS analysis. 
4. The subtracted proteins list is found in Table S3 in the Supporting information of paper IV. 
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identified proteins, bound to Aβ42wt fibril, was noted in samples from patients 
diagnosed with AD5 (paper IV). Proteins identified to bind to Aβ42CC 
protofibrils did not reveal any major differences between AD vs. non-AD group 
(paper III), nonetheless, proteins found to bind Aβ42wt fibrils showed some 
differences between AD vs. non-AD group (paper IV). 
To further access the specificity of the interaction, we studied the binding of 
CSF proteins to non-disease related nanofiber formed by yeast protein Sup35. 
Fibrils formed by Sup35 are similar in structure to Aβ fibrils (Nelson et al., 
2005). One AD and one non-AD CSF sample was tested. Protein binding pattern 
to Sup35 fibrils was different compared to other tested ligands (Fig. 5.8). The 
MS analysis reveals twenty different proteins were bound to Sup35 fibrils (paper 
III). Notably, all these twenty proteins were also found to bind Aβ42wt fibrils 
(paper IV). This result indicates that the surface of the fibrils might have specific 
binding epitopes for these proteins or the proteins have binding sites for fibrils. 
However, several proteins identified in the present study as binding to 
different Aβ conformations have previously been reported to be associated with 
Aβ in AD plaque (Kalaria et al., 1993, McGeer et al., 1994, Liao et al., 2004), 
which indicates that our studies are of relevance to the situation in vivo. 
Moreover, protein identified in our studies may have potential to modulate Aβ 
fibrillation. Indeed, some of the proteins in our list have been shown to modulate 
amyloid formation and toxicity, for examples apolipoprotein A-I (Paula-Lima et 
al., 2009) and apolipoprotein E (Drouet et al., 2001), complement component 
C3q (Pisalyaput and Tenner, 2008) and clusterin (Yerbury et al., 2007). Hence, 
further investigation of protein identified in our studies might lead to new insight 
into the pathways of AD neurodegeneration. 
5.5.2  Aβ species higher in order of aggregation binds more 
proteins  
As stated in previous section, Aβ42wt fibrils attract more proteins than Aβ42CC 
protofibrils (74 for protofibrils vs. 145 for fibrils). In paper III, we studied the 
binding of CSF proteins to monomeric Aβ to compare the outcome with proteins 
identified to bind to two other Aβ conformations. One CSF sample was tested. 
For this test, we chose to use the Aβ40 monomer since the Aβ40 isoform is less 
prone to aggregation than Aβ42 (Burdick et al., 1992, Jarrett et al., 1993). A few 
weak gel bands were visible on an SDS-PAGE in samples from Aβ40 experiment 
(Fig. 5.8, lane: Aβ40wt monomer). The MS result revealed only nine proteins in 
Aβ40wt sample, compared to an average 30 and 80 proteins for Aβ42CC 
protofibrils and Aβ42wt fibrils, respectively. The Aβ species higher in order of 
                                                        
5. See Table S2 in supplementary information of paper IV.  
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the aggregation pathway (monomer ® oligomer/protofibril ® fibril) binds more 
proteins, which suggests that the binding of proteins to Aβ is enhanced upon 
aggregation of Aβ. A more recent study performed by Salza and co-workers 
(Salza et al., 2017) supports our finding. The protein binding differences among 
Aβs and other ligands can be explained by several factors including the 
differences in surface area accessibility, charge and tertiary structure of the 
binding surface, as well as the structural differences of pre-fibrillar and fibrillar 
aggregates. 
5.5.3  Validation of protein binding to different Aβ conformations 
To confirm the binding event of proteins with Aβ42CC protofibril and/or Aβ42wt 
fibrils, SPR-based biosensor studies was performed on selected proteins. The 
SPR results validated the pull-down assay results as well as Aβ conformation-
dependent protein binding. The results are summarized in Table 5.2. The Aβ 
conformation-dependent protein binding in our study agrees well with an earlier 
study (Salza et al., 2017), and indicates that different Aβ nanostructure has a 
distinct set of binding partners. 
Table 5.2 Binding kinetics of the selected proteins to Aβ42CC protofibrils and Aβ42wt fibrils, 
determined by SPR assay. Also includes a comparison of pull-down assay results in terms of yes/no 
binding with SPR results. 
Protein SPR assay Pull-down assay 
 Bound to PF (KD) Bound to F (KD) Bound to PF Bound to F 
Agrin n.d 3.5 nM ´ Ö 
Antithrombin III 0.3 µM n.t Ö Ö 
Apolipoprotein A-I 3 µM n.t Ö Ö 
Apolipoprotein E 3 nM 0.3 nM Ö Ö 
Complement C3 0.6 µM n.t Ö Ö 
Dickkopf-protein 3 n.d 26.2 nM ´ Ö 
Neurocan n.d 11.7 nM ´ Ö 
Osteopontin n.d n.d ´ Ö 
SPARC-like protein 1 n.d 6.2 nM ´ Ö 
PF, protofibrils; F, fibrils; n.d, not determined; n.t, not tested; Ö, yes; ´, no 
 
As seen in Table 5.2, all tested proteins showed high affinity, in the range of low 
micromolar to subnanomolar, to the corresponding Aβ partner. 
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5.5.4  Comparison of protofibrillar and fibrillar Aβ binding-proteins 
Gene ontology (GO) annotation (Mi et al., 2013) into molecular function and 
cellular component were performed. The analysis showed that Aβ42wt fibril-
binding proteins possess binding activity, in contrary, Aβ42CC protofibril-
binding proteins possess catalytic activity. Both aggregate binders are 
predominantly extracellular proteins. The extracellular matrix is an important 
component of the brain, and is associated with various functions such as 
networking (Dauth et al., 2016). It is thought that the Ab fibril formation is 
nucleated on extracellular matrix (Murphy and LeVine, 2010). 
By utilizing the Human Protein Atlas (HPA) tissue-enriched database (Uhlén 
et al., 2015), we identified ten proteins with brain-specific expression pattern 
that associated with Aβ42wt fibril only, but not to the Aβ42CC protofibrils. Fibrils 
are the principal component in the amyloid plaque (Chauhan et al., 2004, 
Chander et al., 2007), and they might have more frequent interaction with brain 
proteins. 
We identified some proteins, bound to Aβ42wt fibril, which may enable the 
discrimination between non-AD and AD CSF and could be of relevance of AD 
biomarkers. Agrin, an extracellular matrix heparan sulphate proteoglycan 
expressed in neurons (Donahue et al., 1999), is an example of such proteins. In 
our study, agrin was found to be abundant in AD CSF. Our result agrees well 
with the existing literature. For examples, Berzin et al. (2000) observed 
increased levels of agrin in CSF of patients with AD compared non-AD CSF 
while Cotman et al.  (2000) reported that agrin is colocalizes with Aβ in amyloid 
plaques and they also showed that agrin bind to Aβ and accelerates Aβ 
fibrillation. Alpha-1-microglobulin/bikunin (AMAB) was found to be abundant 
in non-AD CSF, which corroborates earlier data (Ramström et al., 2003). 
5.5.5  Conclusions 
Aβ was found to interact with a broad range of proteins in serum and CSF. The 
binding of proteins to Aβ is likely governed by the Aβ conformation, and protein 
binding is enhanced upon aggregation of Aβ. Protofibrillar and fibrillar Aβ-
binding protein represent distinct functional categories, and fibril-binding 
proteins are enriched in the brain. Additionally, several of the identified proteins 
might have potential to discriminate between AD vs. non-AD CSF. Taken 
together, our results demonstrate that Aβ aggregates might appear as 
multiprotein aggregates in vivo and that the presence of protein binding partners 
might be important when investigating the cytotoxic mechanisms of protein 
aggregates. 
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An interesting future project would be to identify Ab interacting partners in 
the brain tissue extracts, which would provide greater insight into the Ab 
interactome in the actual brain environment. A second future project would be 
to test the potential of new identified Ab-binders for modulating in vitro Ab 
fibrillation and toxicity in cell culture experiment. Another interesting topic of 
the future study would be to investigate the potential of the binders identified 
here as candidate biomarkers for AD. 
5.6 Concluding remarks 
The molecular biology underlying Ab aggregation and synapse dysfunction in 
AD is poorly understood. However, from a situation where most of the research 
was focused on the mature Ab fibrils, the focus has been shifted to soluble pre-
fibrillar Ab aggregates e.g., oligomers and protofibrils. Considerable evidence 
suggests that oligomers or protofibrils are the most toxic species among other 
Ab species and are correlate well with neuronal death in the AD brain (Walsh et 
al., 2002, Walsh and Selkoe, 2007). However, many questions remain to be 
answered, for instance how do protofibrils exert their toxicity and initiate 
neurodegeneration? Among possible mechanisms, their interactions with other 
proteins have been implicated in these effects (Lee et al., 2017). No significant 
amount of research has been carried out to investigate this aspect. Our studies 
on Aβ-binding protein will add to the knowledge about the complex Aβ-
interactome and its toxicity. 
Although recent studies have helped us to advance our understanding about 
protofibril assembly and their structural properties, much of the details 
surrounding oligomers or protofibrils formations remain elusive. The fact that 
these soluble pre-fibrillar aggregates are heterogeneous and metastable and 
therefore poses a challenge for their detection. Because of its strong association 
with AD, the protofibrils are also the prime target for the development of AD 
treatments, in particular, disease-modifying therapies. Several good antibodies 
have been developed for the detection of oligomer or protofibril (Kayed et al., 
2003, Englund et al., 2007, Kayed et al., 2007). The apparent advantage of our 
new protofibril binders compared to antibodies is their small size. This would 
enable future applications in both therapy and brain imaging since small 
molecules are the primary choice for efficient tissue penetration or passage 
across the blood-brain barrier. 
As a complementary to the traditional amyloid detection techniques e.g. 
Congo red stating, the development of new methods based on biotechnology will 
become valuable tools for clinical identification of amyloid in tissue. Our 
approach of using nanofibrils in amyloid detection system will be an addition in 
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this regard. However, further optimizations and validation are required before it 
can be used in clinical practice.  
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Proteins are the most fundamental molecules in living organisms and are 
involved in almost all biological processes. They are synthesized on ribosomes 
as linear amino acids chains. These chains must then be folded into the correct 
conformation, called native fold of a protein, in order to gain functional activity. 
However, due to mutations, increased production or changes in the cellular 
microenvironment, proteins can be misfolded. If these misfolded proteins escape 
the cellular control system that normally remove the misfolded proteins, proteins 
can aggregate into a highly ordered structure called amyloid fibrils. Deposition 
of amyloid fibrils in tissue is linked to several diseases, for examples, 
Alzheimer’s disease (AD) and transthyretin (ATTR) amyloidosis. To provide 
the best possible treatments, a more complete understanding of the disease 
development and the design of improved diagnostic methods are essential. 
In this thesis, we developed new research tools and method for the detection 
of protein aggregates that caused AD and ATTR amyloidosis. These 
developments have possible applications in the diagnosis of these diseases as 
well as therapeutics. Additionally, we identified many proteins in biofluid that 
interact with AD-causing protein aggregates. This knowledge will help us to 
gain a better understanding of AD. 
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